Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss

Documenti analoghi

• Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
  di: Francesca Vinchi, et al.
  Pubblicazione: (2024)
• Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
  di: Aida Santaolalla, et al.
  Pubblicazione: (2026)
• Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
  di: Cristina A. Tentori, et al.
  Pubblicazione: (2024)
• “Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
  di: Shoshana Burke, et al.
  Pubblicazione: (2025)
• Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
  di: Fabio Efficace, et al.
  Pubblicazione: (2024)